This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fukuda, T. Articles by Sasano, H. Search for Related Content PubMed PubMed Citation Articles by Fukuda, T. Articles by Sasano, H. Related Collections Adrenal and Hypertension

Urocortin 1, Urocortin 3/Stresscopin, and Corticotropin-Releasing Factor Receptors in Human Adrenal and Its Disorders

Departments of Pathology (T.F., T.S., M.S., M.W., H.S.), Molecular Biology and Applied Physiology (K.T.), and Analytical Medical Technology (K.T.), Tohoku University School of Medicine, Sendai 980-8575, Japan; Kyowa Medex Co., Ltd., Research Laboratory (T.F.), Sizuoka 411-0932, Japan; and Kyowa Hakko Kogyo Co., Ltd., Pharmaceutical Marketing Center (T.N.), Tokyo 100-8185, Japan

Address all correspondence and requests for reprints to: Tsuyoshi Fukuda, Department of Pathology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan. E-mail: fukuda{at}patholo2.med.tohoku.ac.jp.

Context: Urocortin 1 (Ucn1) and urocortin 3 (Ucn3)/stresscopin are new members of the corticotropin-releasing factor (CRF) neuropeptide family. Ucn1 binds to both CRF type 1 (CRF₁) and type 2 receptors (CRF₂), whereas Ucn3 is a specific agonist for CRF₂. Recently, direct involvement of the locally synthesized CRF family in adrenocortical function has been proposed.

Objective, Design, and Setting: We examined in situ expression of Ucn and CRF receptors in nonpathological human adrenal gland and its disorders using immunohistochemistry and mRNA in situ hybridization.

Results: Ucn immunoreactivity was localized in the cortex and medulla of nonpathological adrenal glands. Ucn1 immunoreactivity was marked in the medulla, whereas Ucn3 was immunostained mostly in the cortex. Both CRF type 1 and CRF₂ were expressed in the cortex, particularly in the zonae fasciculata and reticularis but very weakly or undetectably in the medulla. Immunohistochemistry in serial tissue sections with mirror images revealed that both Ucn3 and CRF₂ were colocalized in more than 85% of the adrenocortical cells. mRNA in situ hybridization confirmed these findings above. In fetal adrenals, Ucn and CRF receptors were expressed in both fetal and definitive zones of the cortex. Ucn and CRF receptors were all expressed in the tumor cells of pheochromocytomas, adrenocortical adenomas, and carcinomas, but its positivity was less than that in nonpathological adrenal glands, suggesting that Ucn1, Ucn3, and CRF receptors were down-regulated in these adrenal neoplasms.

Conclusions: Ucn1, Ucn3, and CRF receptors are all expressed in human adrenal cortex and medulla and may play important roles in physiological adrenal functions.

This article has been cited by other articles:

				R. Morimoto, F. Satoh, O. Murakami, T. Hirose, K. Totsune, Y. Imai, Y. Arai, T. Suzuki, H. Sasano, S. Ito, et al. Expression of adrenomedullin 2/intermedin in human adrenal tumors and attached non-neoplastic adrenal tissues J. Endocrinol., July 1, 2008; 198(1): 175 - 183. [Abstract] [Full Text] [PDF]

				M. T. Rademaker, C. J. Charles, and A. M. Richards Urocortin 1 administration from onset of rapid left ventricular pacing represses progression to overt heart failure Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1536 - H1544. [Abstract] [Full Text] [PDF]

				E. Dermitzaki, C. Tsatsanis, V. Minas, E. Chatzaki, I. Charalampopoulos, M. Venihaki, A. Androulidaki, M. Lambropoulou, J. Spiess, E. Michalodimitrakis, et al. Corticotropin-Releasing Factor (CRF) and the Urocortins Differentially Regulate Catecholamine Secretion in Human and Rat Adrenals, in a CRF Receptor Type-Specific Manner Endocrinology, April 1, 2007; 148(4): 1524 - 1538. [Abstract] [Full Text] [PDF]

				M. T. Rademaker, V. A. Cameron, C. J. Charles, and A. M. Richards Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure Eur. Heart J., September 1, 2006; 27(17): 2088 - 2098. [Abstract] [Full Text] [PDF]

				E. W. Hillhouse and D. K. Grammatopoulos The Molecular Mechanisms Underlying the Regulation of the Biological Activity of Corticotropin-Releasing Hormone Receptors: Implications for Physiology and Pathophysiology Endocr. Rev., May 1, 2006; 27(3): 260 - 286. [Abstract] [Full Text] [PDF]